Program
elifibranor
Also written as “Elafibranor”, “GFT505 80mg” and “elafibranor”.
Its studies are mostly in Liver Cirrhosis, Biliary · Non-alcoholic Fatty Liver Disease · Cholangitis, Sclerosing · Diabetes Mellitus, Type 2 · Renal Insufficiency, led by 2 companies.
Drug pageElifibranor: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Genfitits history only | 160 open or running | phase 3since Feb 16, 2016 | Dec 13, 2010 | none ahead |
| Ipsen | 85 open or running | phase 3since Aug 21, 2020 | Aug 21, 2020 | Dec 17, 2026phase 3 · NCT06730061 |
Also a collaborator on its studies: Naturalpha, Premier Research Group, Eurofins Optimed and PhinC Development.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Ipsen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 21, 2020First study: phase 3 study in Liver Cirrhosis, BiliaryFirst studyNCT04526665 · 161 enrolled · United States, Argentina, Belgium and more
- Sep 14, 20222 phase 1 studiesNCT05543369, NCT05564208
- Nov 22, 2022Phase 2 study in Cholangitis, SclerosingNCT05627362 · 68 enrolled · United States, Canada, Germany and more
- Aug 22, 2023Phase 3 study in Liver Cirrhosis, BiliaryNCT06016842 · 276 planned · United States, Argentina, Australia and more
- Apr 22, 2024Phase 3 study in Liver Cirrhosis, BiliaryNCT06383403 · 92 enrolled · United States, Czechia, France and more
- Dec 3, 2024Phase 3 study in Liver Cirrhosis, BiliaryNCT06730061 · 18 enrolled · Japan
- Jan 28, 2026Phase 3 study in Cholangitis, SclerosingNCT07387549 · 350 planned · United States, Argentina, Australia and more
Ahead
- Dec 17, 2026Primary completion: phase 3 study in Liver Cirrhosis, BiliaryNCT06730061
- May 31, 2029Primary completion: phase 3 study in Liver Cirrhosis, BiliaryNCT06016842
- Apr 30, 2031Primary completion: phase 3 study in Cholangitis, SclerosingNCT07387549
- Sep 23, 2031Primary completion: phase 2 study in Cholangitis, SclerosingNCT05627362
TargetBeta
“An orally bioavailable agonist of peroxisome proliferator-activated receptor (PPAR)-alpha (PPARa) and -delta (PPARd), with bile acids reducing activity”NCIt, by rule
Other programs on PPARA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| saroglitazarrule | Zydus Lifesciences | phase 4 | 19 |
| pemafibraterule | Kowa | phase 4 | 17 |
| seladelparrule | Gilead Sciences | phase 3 | 14 |
| chiglitazarrule | Chipscreen Biosciences | phase 3 | 9 |
| Gemfibrozilrule | polaryx-therapeutics-inc | phase 3 | 8 |
| lanifibranor | inventiva-pharma | phase 3 | 6 |
Studies
All 8 Ipsen leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07387549Cholangitis, Sclerosing · United States, Argentina, Australia and more | 3 | Recruiting | Apr 30, 2031 | 350 |
| NCT06730061Liver Cirrhosis, Biliary · Japan | 3 | Active, not recruiting | Dec 17, 2026 | 18 |
| NCT06383403Liver Cirrhosis, Biliary · United States, Czechia, France and more | 3 | Completed | Jun 16, 2026 | 92 |
| NCT06016842Liver Cirrhosis, Biliary · United States, Argentina, Australia and more | 3 | Recruiting | May 31, 2029 | 276 |
| NCT05627362Cholangitis, Sclerosing · United States, Canada, Germany and more | 2 | Active, not recruiting | Sep 23, 2031 | 68 |
| NCT05564208Healthy Participants · France | 1 | Completed | Dec 30, 2022 | 34 |
| NCT05543369Healthy Volunteers · United States | 1 | Completed | Mar 10, 2023 | 48 |
| NCT04526665Liver Cirrhosis, Biliary · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Jun 1, 2023 | 161 |
How it is read
Names in the registry
- “Elafibranor”, 8 entries
- “GFT505 80mg”, 5 entries
- “elafibranor”, 4 entries
- “Elafibranor 80mg”, 2 entries
- “Elafibranor 80 mg”, 2 entries
Conditions, from the studies’ own filings
- Liver Cirrhosis, Biliary, 5 studies
- Non-alcoholic Fatty Liver Disease, 4 studies
- Cholangitis, Sclerosing, 2 studies
- Diabetes Mellitus, Type 2, 2 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.